Search results
Showing 1 to 15 of 33 results for ibrutinib
Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA795)
Evidence-based recommendations on ibrutinib (Imbruvica) for Waldenstrom’s macroglobulinaemia in adults who have had at least 1 previous therapy.
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)
Evidence-based recommendations on ibrutinib (Imbruvica) with venetoclax (Venclyxto) for untreated chronic lymphocytic leukaemia in adults.
Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)
Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma in adults.
Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.
NICE is unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults. This is because Janssen did not provide an evidence submission.
Show all sections
Sections for TA608
In development Reference number: GID-TA10046 Expected publication date: 22 November 2017
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) (TA703)
NICE is unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for untreated chronic lymphocytic leukaemia because Janssen did not provide an evidence submission.
Show all sections
Sections for TA703
In development Reference number: GID-TA11495 Expected publication date: 07 January 2026
NICE is unable to make a recommendation on ibrutinib (Imbruvica) with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma in adults because Janssen did not provide an evidence submission.
Show all sections
Sections for TA702
NICE is unable to make a recommendation about the use in the NHS of ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation because no evidence submission was received from Janssen–Cilag.
Show all sections
Sections for TA452
NICE is unable to make a recommendation about the use in the NHS of ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy. This is because Janssen-Cilag did not provide an evidence submission.
Show all sections
Sections for TA437
In development Reference number: GID-TA11802 Expected publication date: TBC
Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)
Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults.
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma (TA1081)
Evidence-based recommendations on zanubrutinib for treating relapsed or refractory mantle cell lymphoma in adults who have had 1 line of treatment only.